Nugen Technologies Inc

Tecan Genomics, Inc., based in Redwood City, CA, specializes in providing innovative solutions for liquid handling automation and life sciences diagnostics. With a strong commitment to sustainability and quality, the company offers a wide range of products and services designed to enhance research and development across various fields, including genomics and proteomics. Recognized for its meaningful work culture, Tecan fosters an environment shaped by core values that prioritize collaboration and innovation. The company's comprehensive portfolio includes advanced technologies like automated systems, microplate readers, and various consumables that support applications in drug discovery, clinical diagnostics, and more. Generated from the website

OncoMed Pharmaceuticals, founded in 2004, is a biotechnology company that deals in providing cancer treatment for individuals. The company conducts cancer stem cell research programs and has established a library of antibodies for the treatment of solid tumors, such as pancreatic, breast, colorectal and lung cancer. It is a privately owned company that receives funds from a group of investors, including US Venture Partners, Latterell Venture Partners(LVP), The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures Limited, Delphi Ventures, Adams Street Partners, De Novo Ventures and Bay Partners. OncoMed Pharmaceuticals OncoMed has established various technologies for the detection, isolation and characterization of tumor initiating cells. The company has tested more than 150 antibodies.

Codexis, Inc., based in Redwood City, CA, is a leading enzyme engineering company known for its proprietary CodeEvolver technology platform. Specializing in the discovery, development, and enhancement of high-performance enzymes and other proteins, Codexis tackles challenges in small molecule pharmaceutical manufacturing and nucleic acid synthesis. The company is at the forefront of developing the ECO Synthesis platform to facilitate the large-scale production of RNAi therapeutics through an enzymatic approach, offering solutions for improved yields, energy efficiency, waste reduction, and enhanced sensitivity in genomic and diagnostic applications. With a focus on driving innovation and sustainability in enzyme technology, Codexis' unique enzymes are designed to optimize manufacturing processes, delivering tangible benefits such as increased efficiency and reduced environmental impact. Leveraging its expertise in enzyme-catalyzed reactions, Codexis is committed to advancing the field of biocatalysis and shaping the future of precision medicine and biopharmaceutical production.Generated from the website